OpenAIR @ RGU >
Health and Social Care >
Centre for Obesity Research and Epidemiology >
Journal articles (Centre for Obesity Research and Epidemiology) >

Please use this identifier to cite or link to this item:
This item has been viewed 5 times in the last year. View Statistics

Files in This Item:

File Description SizeFormat
Broom IJCP 2011 over-the-counter orlistat.pdf835.9 kBAdobe PDFView/Open
Title: Over-the-counter Orlistat: early experiences, views and attitudes of community pharmacists in Great Britain.
Authors: Weidman, Anita Elaine
Cunningham, Scott
Gray, Gwen
Hansford, Denise
McLay, James
Broom, John
Stewart, Derek C.
Keywords: Community pharmacist
Great Britain
Over-the-counter medicines
Pharmacist experience
Pharmacist views
Issue Date: Aug-2011
Publisher: Springer Verlag
Citation: WEIDMAN, A. E., CUNNINGHAM, S., GRAY, G., HANSFORD, D., MCLAY, J., BROOM, J. and STEWART, D., 2011. Over-the-counter Orlistat: early experiences, views and attitudes of community pharmacists in Great Britain. International Journal of Clinical Pharmacy, 33 (4), pp. 627-633.
Abstract: Objectives of the study To describe community pharmacists’ early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010. Setting 13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200. Methods A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply. Main outcome measures Pharmacists’ early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat. Results Questionnaires were returned by 32.4% (n = 4,026) of pharmacists surveyed. Just over half (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 203) reporting frequent (5.1%) or very frequent supply in the same time frame. Two thirds (66.5%, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92% (n = 3,712) felt confident in their ability to supply this product. Over half (57.9%, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8% (n = 1,926) agreed that customers could misuse the product. Conclusion Despite community pharmacists welcoming orlistat re-classification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.
ISSN: 2210-7703
Appears in Collections:Journal articles (Centre for Obesity Research and Epidemiology)

All items in OpenAIR are protected by copyright, with all rights reserved.


   Disclaimer | Freedom of Information | Privacy Statement |Copyright ©2012 Robert Gordon University, Garthdee House, Garthdee Road, Aberdeen, AB10 7QB, Scotland, UK: a Scottish charity, registration No. SC013781